Challenger

Challenger
CME and Preparatory ProductsProgramsWeb ProductsReviewsTech SupportFrequently Asked Questions


Quick Quiz Newsletter
compliments of Challenger Corporation

Click image to enlarge
1.

Click image to enlarge
2.
 


Med-Challenger FM Career
Comprehensive Review and Assessment for Practicing
Family Physicians


For more information on Challenger's boards preparation, clinical review, and other electronic resources for physicians, visit www.chall.com, or call a Challenger Sales Representative at
1-800-676-0822, ext. 4400.

Try Our Products!
Click Here for a Free Demonstration
.

 

 


Issue: February 15, 2007
Case: Drug, Electrolyte, and Metabolic Problems
Taken from
Med-Challenger FM Career
All Products | Challenger Corporation
Click Here for a Free Product Demonstration.

Question:

A 75-year-old woman, accompanied by her daughter, arrives for evaluation. The patient, normally alert, oriented, and fully functional, is obviously experiencing visual and auditory hallucinations. She is agitated and fearful. The patient's neighbor contacted her family when she was observed trying to back her automobile out of a garage. She appeared disoriented at that time, and did not seem to recognize her neighbor.

Her medical history includes chronic hypertension, irritable bowel syndrome, and insomnia. Her medications include an over-the-counter antacid, Lomotil for diarrhea, a diuretic, and diphenhydramine for sleep.

She has a temperature of 100.9, heart rate of 160, and blood pressure of 180/110. Her skin is hot, dry and flushed. Mucus membranes are dry. Pupils are dilated bilaterally. WBC is 14,800.

Her ECG is displayed to the right (Click here to enlarge Image 1).  Considering the history and clinical findings, what is the most likely diagnosis?
  1. senile dementia
  2. acute psychosis
  3. sepsis
  4. anticholinergic toxicity
  5. ketoacidosis
     

Answer:
D

Remediation:
This patient is taking two medications containing anticholinergic agents, Lomotil (with atropine) and diphenhydramine. Atropinism has been caused by normal doses of atropine and homatropine eye drops. The central nervous system actions of atropine and atropine-like drugs are attributed to the blockade of muscarinic synapses.

Bronchodilator inhaler overuse can produce similar symptoms. Commercially available teas (thorn apple) and teas prepared with plants containing atropine have produced serious intoxication. Leukocytosis may occur, confusing the diagnosis.

A diagnosis of dementia or psychosis should be considered only after medical causes are excluded.

ECG findings associated with atropine or anticholinergic toxicity may include:
  • Tachycardia
  • Atrial arrhythmias
  • Wandering pacemaker
  • Second degree AV block
  • AV dissociation
     

About the Image(s):
Image 1:
ECG: Sinus Tachycardia and Left Ventricular Hypertrophy
The ECG of this 75-year-old woman shows:

  • Sinus tachycardia, rate 163
  • One atrial premature complex or ventricular premature complex with fusion, which occurred during recording of the lateral chest leads
  • Probable left ventricular hypertrophy with ST-T repolarization abnormalities
  • Borderline low voltage in the frontal leads
  • Poor R wave progression, possibly due to left ventricular hypertrophy
  • Marked anterior ST segment elevation, possibly due to left ventricular hypertrophy, tachycardia

Image 2: Typical Normal Adult ECG for Comparison
This ECG of a 53-year-old male shows:

  • Normal sinus rhythm, rate 87


CAN YOU WRITE A BETTER QUESTION?  Give it a try and WIN!
Submit your own clinical quiz Q&A and win a FREE Challenger Atlas product in our Quick Quiz Challenge 
VIEW DETAILS HERE.

View past newsletters here


If you received this newsletter from a friend, Click here to receive your own Quick Quiz Newsletter.

Compliments of Challenger Corporation
5100 Poplar Avenue, Ste. 1410
Memphis, TN 38137

Challenger Corporation respects your privacy. To unsubscribe from this email, send an email to removeme@chall.com. Please specify your name and email address to ensure accuracy.


Copyright © Challenger Corporation All rights reserved.